App-Quantinova.ai

Real world data examining the use of Ixazomib, Lenalidomide and Dexamethasone (ILD) and Lenalidomide and Dexamethasone (LD) chemotherapy in Multiple Myeloma

Zara Sayar - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Dexamethasone

CHARACTERISTICS AND REAL-WORLD TREATMENT OUTCOMES IN MULTIPLE MYELOMA YOUNG PATIENTS: A SINGLE CENTER MOROCCAN EXPERIENCE

El Mehdi Mahtat - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Frequency of Hypercoagulability in Patients With Embolic Stroke of Undetermined Source and Patent Foramen Ovale

Michael Liu - International Stroke Conference (ISC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Hemostatic Solution

Von Willebrand Factor Expression in Various Subtypes of Acute Ischemic Stroke

Oana M Mereuta - International Stroke Conference (ISC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Cerebral Venous Thrombosis Caused by Congenital Thrombophilia in Japan

Akihiro Shindo - International Stroke Conference (ISC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

PREVALENCE OF JAK2V617F, CALR AND MPL MUTATIONS IN PATIENTS OF MYELOPROLIFERATIVE NEOPLASMS AND SPLANCHNIC VEIN THROMBOSIS IN INDIA

Jasmita - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

GLOBAL COAGULATION CAPACITY OF ESSENTIAL THROMBOCYTHEMIA PATIENTS BY ROTEM ANALYSIS ADJUSTED FOR PLATELET COUNT CORRELATES WITH THROMBOTIC RISK CLASS

Cinzia Giaccherini - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

THREE-YEAR ANALYSIS OF THE DALIAH TRIAL - A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA-2 VS. HYDROXYUREA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

Trine Alma Knudsen - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Interferon alpha

MULTICENTER RETROSPECTIVE STUDY EVALUATING FIBROSIS RISK IN PATIENTS WITH ET DEPENDING ON THE TREATMENT SCENARIO

Marta Sobas - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

RISK OF THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA ACCORDING TO THE JAK2 V617F ALLELE BURDEN

Sung Hwa Bae - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

RATE OF THROMBOSIS IN CONTEMPORARY PATIENTS WITH POLYCYTHEMIA VERA UNDER HYDROXYUREA REMAINS EXCEEDINGLY HIGH. RESULTS OF SYSTEMATIC REVIEW AND METANALYSIS.

Alberto Ferrari - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Hydroxyurea

MOLECULAR PROFILE AND RISK OF THROMBOSIS IN JAK2V617F POLYCYTHEMIA VERA PATIENTS

Anna Angona - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

MAJOR OR CLINICALLY RELEVANT NON-MAJOR HEMORRHAGIC EVENTS IN A LARGE POPULATION OF PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA: LOCALIZATION, CONSEQUENCES AND DRUG USE

Christophe Nicol - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

ARTERIAL THROMBOSIS IN YOUNG PV PATIENTS

Giulia Bogoni - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Aspirin

HEALTHCARE RESOURCE IMPLICATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND SPLANCHNIC VEIN THROMBOSIS

Ximena Cabrera Castellano - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Aspirin

JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS.

Mirko Farina - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

ARTERIAL AND VENOUS THROMBOSIS IN TREATED PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

Ana Boban - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Methadone hydrochloride

Incidence of Deep Venous Thrombosis Following Endovascular Revascularization via the Femoral Artery Due to Acute Ischemic Stroke

Nozomi Chiba - International Stroke Conference (ISC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

: RISK FACTORS OF THROMBOSIS AFTER MPN DIAGNOSIS: A RETROSPECTIVE COHORT OF MPN PATIENTS IN BRAZIL

Larissa Lane Cardoso Teixeira - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

APPLICATION OF WHOLE EXOME SEQUENCING FOR PATIENTS WITH INHERITED PLATELET DISORDERS

Marian Stevens-Kroef - European Hematology Association (EHA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

Filters

7277 Abstracts